MLN8237: Phase II data

In an open-label, U.S Phase II trial in 31 patients with platinum-resistant or refractory ovarian (n=25), primary peritoneal (n=5) or fallopian tube carcinomas (n=1), oral MLN8237 produced 3 partial r...